Fig. 3From: Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancerProgression-free survival of patients. AP group (n = 149; black triangles), EP group (n = 150; red circles) (ITT population). AP, amrubicin/cisplatin; CI, confidence interval; EP, etoposide/cisplatin; HR, hazard ratio; ITT, intent-to-treatBack to article page